Cory Dion Littau Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4545 W 6th Ave, Stillwater, OK 74074 Phone: 405-707-0756 |
Cody L Canary, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 111 N Perkins Rd, Stillwater, OK 74075 Phone: 405-372-2897 |
Steven Willingham, D.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 722 S Main St, Stillwater, OK 74074 Phone: 405-372-6120 Fax: 405-372-2833 |
Dr. Diana Marcela Hess, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 519 S Main St, Stillwater, OK 74074 Phone: 405-377-0349 |
Dr. Lisa Dianne Wiegleb, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 519 S Main St, Stillwater, OK 74074 Phone: 405-377-0349 Fax: 405-377-0167 |
Denise Larimore, DPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 421 N Main St, Stillwater, OK 74075 Phone: 405-743-1080 Fax: 405-372-4872 |
Jane L. West, D. PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1721 W 6th Ave, Stillwater, OK 74074 Phone: 405-372-3331 Fax: 405-372-3547 |
Alyson Nicole Armour Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2315 N Perkins Rd, Stillwater, OK 74075 Phone: 405-564-7115 |
Melissa Ann Petersen-gent, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1220 W 12th Ave, Stillwater, OK 74074 Phone: 405-372-6120 |
Barry Lynn Brian, D.PH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 519 S Main St, Stillwater, OK 74074 Phone: 405-377-0349 Fax: 405-377-0169 |
Dr. Alan Ray Seefeldt, DPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1723 W 6th Av, Stillwater, OK 74074 Phone: 405-372-3331 Fax: 405-372-3547 |
Carla Kay Knight, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 825 S Walnut St, Stillwater, OK 74074 Phone: 405-372-7900 Fax: 405-377-5139 |
News Archive
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, announced today that it has completed its previously announced registered direct offering of US$15 million of units comprised of common shares and common share purchase warrants to certain institutional investors.
One of the members of the advisory panel set up to discuss the future of the diabetes pill Avandia says it should be removed from the market because it is too risky and offers no advantage over other alternatives.
Our responsiveness to seeing others in distress accounts for variability in helping behavior from early in development, according to a study published Sept. 25 in the open-access journal PLOS Biology by Tobias Grossmann from the Max Planck Institue for Human Cognitive and Brain Sciences (MPI CBS) and the University of Virginia, and his team.
The goal will be to ensure the program's fiscal sustainability into the future — a frequent criticism from GOP critics who hope to repeal the program.
› Verified 4 days ago